Fig. 2: Melanoma specimens reduce PRGs positive cells in epidermal clinically.

A Overall survival analysis based on K-M was calculated to identify the potential PRGs clinically. B PPI via MCODE and CytoNCA algorithm was established, in which PRGs were screened out as central protein functioning in melanoma deficiency. C GZMA, GSDMB, CHMP4A, NLRP1, and IL18 protein expression of melanoma and control patients detected by ELISA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 5, compared with the normal group. D Representative IHC stanning of GZMA⁺, GSMDB⁺, CHMP4A⁺, NLRP1⁺, and IL18⁺ in melanoma specimens from the clinic. Scale bar = 100 μm, n = 5 samples per group. E The quantification of PRGs protein in epidermal areas, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, compared with the control group.